#Peripheral Neuropathy Market Size

[creativecontentcraze]

Peripheral Neuropathy Treatment Market Anticipated To Witness High Growth Owing To Increasing Prevalence Of Diabetes

Peripheral neuropathy treatment involves the treatment of diseases of the peripheral nervous system, which can cause numbness, pain, tingling, and weakness. Peripheral neuropathies can affect both the sensory and motor functions of peripheral nerves. The symptoms can range from mild to severe depending on the cause of neuropathy. The main causes of peripheral neuropathies include diabetes, alcohol consumption, infection such as HIV, and autoimmune disorders.

The global peripheral neuropathy treatment market is estimated to be valued at US$ 2146.54 Bn in 2024 and is expected to exhibit a CAGR of 19% over the forecast period 2024 To 2031. Key Takeaways Key players operating in the peripheral neuropathy treatment market are DMedHOK, Inc., Safecare Technology, Octal IT Solution, McKesson Corporation, LS Retail ehf., Liberty Software, Inc., GlobeMed Group, Datascan, Cerner Corporation, Allscripts Healthcare, LLC, and Epicor Software Corporation, among others. The key players are focusing on new product launches, mergers, acquisitions, and partnerships to gain a competitive advantage in the market. For instance, in April 2022, NeuPath Health launched a new peripheral neuropathy treatment program with advanced diagnostics and integrated care to improve treatment outcomes. The increasing adoption of digital technologies such as AI, analytics, and robotic process automation by healthcare providers provides lucrative growth opportunities in the market. Manufacturers are developing telemetry-enabled, wearable medical devices for remote monitoring and quick response to peripheral neuropathy treatment market symptoms, especially for patients living in remote areas. There is huge potential for market expansion in the Asia Pacific region due to the rising geriatric population, increasing healthcare expenditure, growing prevalence of diabetes, and favorable government policies in countries such as China and India. Key players are focusing on expanding their distribution networks in emerging economies to tap the large patient pool in the Asia Pacific region. Market Drivers Increasing prevalence of diabetes: According to IDF, the global prevalence of diabetes among adults over 18 years of age has risen to 10.5% in 2019 and is projected to increase to 12.2% by 2030. Diabetes is the leading cause of peripheral neuropathy and the increasing diabetes patient pool is driving market growth. Rising healthcare expenditure: Rising healthcare spending on chronic disease management provides an impetus to market growth. For instance, the US healthcare spending is projected to grow at an annual rate of 5.4% from 2020 to 2028 and reach USD 6.2 trillion by 2028. With the aging population and increasing prevalence of peripheral neuropathy, healthcare providers are expected to spend more on neuropathy treatment. Market Restrains High cost of advanced treatment options: Advanced treatment options such as electrical stimulation therapy, electromagnetic therapy, and cryotherapy procedures involve high upfront costs which can hinder patient access and adoption, especially in developing countries. This can restrain market potential to some extent. Limited awareness in developing nations: Peripheral neuropathy awareness still remains relatively low in developing nations where majority cases go undiagnosed due to limited access to healthcare resources. This lack of awareness acts as a market barrier.

Segment Analysis The Peripheral Neuropathy Treatment market can be segmented into drug class, route of administration, distribution channel, and indication. Based on drug class, the market is dominated by pregabalin currently owing to the lack of newer approved products, proven efficacy to alleviate pain associated with neuropathy. However, in the coming years, the antidepressants sub-segment is expected to gain market share due to the off-label usage of antidepressants for the treatment of neuropathy. Based on the route of administration, the oral segment holds a significant share as oral drugs are convenient to use. The topical segment is also growing steadily owing to benefits such as direct site action, avoidance of first-pass metabolism resulting in reduced side effects. In terms of distribution channel, hospital pharmacies maintain dominance as neuropathy patients prefer hospitals for prescription drugs along with medical advice. However, the increasing internet penetration and rising online pharmacy platforms are expected to boost the growth of the retail pharmacy segment during the forecast period. Based on indication, diabetic neuropathy remains the major application area of peripheral neuropathy treatment drugs. This is because diabetic neuropathy is the most common form of neuropathy, accounting for more than 50% of neuropathy cases worldwide. Global Analysis On the regional front, North America is projected to command the maximum share in the global peripheral neuropathy treatment market during the forecast period. The increasing prevalence of diabetes and subsequent rise in diabetic neuropathy cases, expanding geriatric population in the U.S. and Canada and availability of new drugs and treatment options in North America is expected to keep the region at the forefront. However, Asia Pacific is anticipated to witness lucrative growth prospects, especially in India and China. This is credited to the presence of a large patient pool, rising healthcare spending, and improving access to healthcare in APAC countries. At country-level, the U.S. leads the North American peripheral neuropathy treatment market aided by its well-established healthcare system and presence of key market players. Germany dominates the European peripheral neuropathy treatment market attributed to the rising research activities and increasing healthcare spending in the country.

Get More Insights On, Peripheral Neuropathy Treatment Market

About Author:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)

[deshpandeisha]

Understanding Peripheral Neuropathy: Causes, Symptoms, and Types

The global peripheral neuropathy market size was USD 3.61 Billion in 2022 and is expected to register a revenue CAGR of 9.0% during the forecast period. Rise in peripheral neuropathy cases, the increased prevalence of chronic illnesses, and increasing number of pipeline drugs are some of the key factors driving market revenue growth.

The Global Peripheral Neuropathy Market Report, published by Emergen Research, offers an industry-wide assessment of the Peripheral Neuropathy market, which is inclusive of the most crucial factors contributing to the growth of the industry. The latest research report comprises an extensive analysis of the micro- and macro-economic indicators that influence the global market development during the forecast period.

Get Download Pdf Sample Copy of this Report@ https://www.emergenresearch.com/request-sample/2757

Competitive Terrain:

The global Peripheral Neuropathy industry is highly consolidated owing to the presence of renowned companies operating across several international and local segments of the market. These players dominate the industry in terms of their strong geographical reach and a large number of production facilities. The companies are intensely competitive against one another and excel in their individual technological capabilities, as well as product development, innovation, and product pricing strategies.

The leading market contenders listed in the report are:

Assertio Holdings, Inc, AstraZeneca, Abbott, Cadila Pharmaceuticals, Cipla Inc, DAIICHI SANKYO COMPANY, LIMITED, Dr. Reddy’s Laboratories Ltd, Eli Lilly and Co., Endo International plc, Grünenthal, Hikma Pharmaceuticals PLC, Johnson & Johnson, Inc, Lupin, Novartis AG, Pfizer Inc, Shionogi & Co., Ltd, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, UCB S.A., Viatris Inc

Key market aspects studied in the report:

Market Scope: The report explains the scope of various commercial possibilities in the global Peripheral Neuropathy market over the upcoming years. The estimated revenue build-up over the forecast years has been included in the report. The report analyzes the key market segments and sub-segments and provides deep insights into the market to assist readers with the formulation of lucrative strategies for business expansion.

Competitive Outlook: The leading companies operating in the Peripheral Neuropathy market have been enumerated in this report. This section of the report lays emphasis on the geographical reach and production facilities of these companies. To get ahead of their rivals, the leading players are focusing more on offering products at competitive prices, according to our analysts.

Report Objective: The primary objective of this report is to provide the manufacturers, distributors, suppliers, and buyers engaged in this sector with access to a deeper and improved understanding of the global Peripheral Neuropathy market.

Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now)@ https://www.emergenresearch.com/request-discount/2757

Market Segmentations of the Peripheral Neuropathy Market

This market is segmented based on Types, Applications, and Regions. The growth of each segment provides accurate forecasts related to production and sales by Types and Applications, in terms of volume and value for the period between 2022 and 2030. This analysis can help readers looking to expand their business by targeting emerging and niche markets. Market share data is given on both global and regional levels. Regions covered in the report are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Research analysts assess the market positions of the leading competitors and provide competitive analysis for each company. For this study, this report segments the global Peripheral Neuropathy market on the basis of product, application, and region:

Segments Covered in this report are:

Type Outlook (Revenue, USD Billion; 2019-2032)

Diabetic Peripheral Neuropathy

Chemotherapy-Induced Peripheral Neuropathy

Idiopathic Peripheral Neuropathy

HIV/AIDS Associated Peripheral Neuropathy

Treatment Method Outlook (Revenue, USD Billion; 2019-2032)

Pharmacological Therapies

Pain Relievers

Anti-Seizure Medications

Anti-Depressants

Non-Pharmacological Therapies

Transcutaneous Electrical Nerve Stimulation

Plasma Exchange

Others

Others

Route of Administration Outlook (Revenue, USD Billion; 2019-2032)

Oral

Parenteral

Others

Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/peripheral-neuropathy-market

Major Geographies Analyzed in the Report:

North America (U.S., Canada)

Europe (U.K., Italy, Germany, France, Rest of EU)

Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)

Latin America (Chile, Brazil, Argentina, Rest of Latin America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

ToC of the report:

Chapter 1: Market overview and scope

Chapter 2: Market outlook

Chapter 3: Impact analysis of COVID-19 pandemic

Chapter 4: Competitive Landscape

Chapter 5: Drivers, Constraints, Opportunities, Limitations

Chapter 6: Key manufacturers of the industry

Chapter 7: Regional analysis

Chapter 8: Market segmentation based on type applications

Chapter 9: Current and Future Trends

Request Customization as per your specific requirement@ https://www.emergenresearch.com/request-for-customization/2757

About Us:

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: www.emergenresearch.com

Direct Line: +1 (604) 757-9756

E-mail: sales@emergenresearch.com

Visit for More Insights: https://www.emergenresearch.com/insights

Explore Our Custom Intelligence services | Growth Consulting Services

Trending Titles: Geocell Market | Pancreatic Cancer Treatment Market

Latest Report:  Ceramic Tiles Market | Life Science Analytics Market

[global-research-report]

The Future of Diagnostics: A Deep Dive into Point of Care Testing

The global point of care diagnostics market size is expected to reach USD 68.5 billion by 2030, registering a CAGR of 6.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. The introduction of advanced technologies such as Telehealth enabled POCT is expected to fuel market growth. Furthermore, the rise in the geriatric population and their need for accessible home-based care are anticipated to drive the market.

The adoption of POCT in emerging economies such as Africa and Latin America is anticipated to be a growth determinant of the global POCT market. The authorities are decentralizing the healthcare system and increasing their investments. For instance, the African regulations in Kenya allotted USD 346.7 to Managed Equipment Services project for the government's initiative toward modernizing facilities by procuring new equipment. The Ministry of Health selected GE Health and Philips to offer equipment across 47 countries. Similarly, Latin America decentralized IVD testing, which encourages private players to take strategic initiatives to meet the region’s existing demand for affordable POCT, especially in the infectious diseases segment.

Currently developed POC devices and tests are employed across different medical diagnostic applications, including cancer, pregnancy, and infectious diseases. Patients and physicians employ POC tests to screen conditions, confirm diagnoses, and design suitable therapeutic approaches based on patient health. However, the enthusiasm displayed by different consumers, such as doctors, patients, and caregivers, varies widely. This dynamic consumption pattern of POC diagnostic products is also attributed to economic scalability, financial interests, and lack of a universal healthcare structure.

In the light of COVID-19, the lockdown imposed across the globe has necessitated virtual visits and rapid diagnostic tests that assist patients to avoid hospital visits. Post-lockdown, the eHealth strategy is the emerging area of priority and investment such as an automated patient appointment system, lab result transmission system, healthcare workers' communication system, and medical products procurement system for the companies and governments. It is anticipated to continue to prioritize home-based healthcare delivery even after the pandemic, especially for patients with pre-existing conditions. For instance, NeuroMetrix, Inc. appointed a team to develop the business of DPNCheck, a POCT for peripheral neuropathies. The team is responsible for expanding the footprint in the healthcare market and focusing on the Medicare Advantage population. 

Point Of Care Diagnostics Market Report Highlights

The Infectious disease led the market and accounted for 27.8% of global revenue share in 2023. Growth of the segment is attributed to increasing demand for rapid tests, which has encouraged industry players to deliver point of care solutions to decentralized regions and launch innovative solutions.

Home sector is projected to witness the highest growth rate over the forecast period owing to the comfort level and cost-effectiveness of point of care diagnostics provided to patients at home. POCT devices are easy to use and do not, mandatorily, require any modern lab infrastructure for testing simpler target analytes in a patient's sample

North America dominated the market and accounted for a 42.9% share in 2023 owing to the increasing demand for new technologies, a large pool of key players, and advanced healthcare infrastructure

The Asia Pacific is anticipated to witness significant growth in the market owing to the rising prevalence of cancer, diabetes, cardiovascular diseases, and infectious diseases. The increasing population with limited disposable income is the potential target market for the key players in the region

Point Of Care Diagnostics Market Segmentation

Grand View Research has segmented the global point of care diagnostics market on the basis of on product, end use, and region:

Point Of Care Diagnostics Product Outlook (Revenue, USD Billion, 2018 - 2030)

Glucose Testing

Hb1Ac Testing

Coagulation Testing

Fertility/Pregnancy

Infectious Disease

HIV POC

Clostridium Difficile POC

HBV POC

Pneumonia or Streptococcus Associated Infections

Respiratory Syncytial Virus (RSV) POC

HPV POC

Influenza/Flu POC

HCV POC

MRSA POC

TB and Drug-resistant TB POC

HSV POC

COVID-19

Other Infectious Diseases

Cardiac Markers

Thyroid Stimulating Hormone

Hematology

Primary Care Systems

Decentralized Clinical Chemistry

Feces

Lipid Testing

Cancer Marker

Blood Gas/Electrolytes

Ambulatory Chemistry

Drug of Abuse (DOA) Testing

Autoimmune Diseases

Urinalysis/Nephrology

Point Of Care Diagnostics End-use Outlook (Revenue, USD Billion, 2018 - 2030)

Clinics

Hospitals

Home

Assisted Living Healthcare Facilities

Laboratory

Point Of Care Diagnostics Regional Outlook (Revenue, USD Billion, 2018 - 2030)

North America

US

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Denmark

Sweden

Norway

Asia Pacific

Japan

China

India

South Korea

Australia

Thailand

Latin America

Brazil

Mexico

Argentina

Middle East and Africa (MEA)

South Africa

Saudi Arabia

UAE

Kuwait

List of Key Players of Point Of Care Diagnostics Market

Hoffmann-La Roche Ltd.

Qiagen

Danaher Corporation

Becton Dickinson (BD)

bioMérieux

Abbott

Siemens Healthcare GmbH

Werfen

Nova Biomedical

Trividia Health, Inc.

QuidelOrtho Corporation

Trinity Biotech

Sekisui Diagnostics

Orasure Technologies, Inc.

Spectral Medical, Inc.

EKF Diagnostics Holdings plc.

Anbio Biotechnology Co., Ltd.

AccuBioTech Co., Ltd

ALPHA LABORATORIES.

Order a free sample PDF of the Point Of Care Diagnostics Market Intelligence Study, published by Grand View Research.

[industrynewsupdates]

Exploring Diabetic Neuropathy Management Market: Trends and Future Outlook

The global diabetic neuropathy management market size was estimated at USD 2.62 billion in 2023 and is expected to grow at a CAGR of 5.8% from 2024 to 2030. Major factors contributing to the market growth include the growing prevalence of diabetes, the rising geriatric population, technological advancements, increased in R&D activities, and the increase in number of product approvals. According to Centers for Disease Control and Prevention (CDC) statistics, approximately 11.6% of the U.S. population, or 38.4 million Americans, live with diabetes and are estimated that half of these individuals are likely to develop diabetic neuropathy at some point during their lifetime.

High prevalence of diabetes is the major factor driving the market growth. Diabetes, when left unmanaged, can lead to a range of serious complications, including peripheral neuropathy. According to the International Diabetes Federation (IDF), 537 million adults worldwide lived with diabetes in 2021, it further states that the number is expected to surge to 642 million by 2040. The prevalence of diabetes is increasing globally, with the most significant rises observed in low- and middle-income countries. The Western Pacific, South Asia, and Europe had the highest numbers of adults living with diabetes in 2021, at 167 million, 88 million, and 59 million respectively.

Gather more insights about the market drivers, restrains and growth of the Diabetic Neuropathy Management Market

Key Diabetic Neuropathy Management Company Insights

The major players in the diabetic neuropathy management market are actively enhancing their product portfolios through various strategies aimed at staying competitive and expanding their market share. This includes continuous product upgrades to incorporate the latest technological advancements, strategic collaborations, and exploring acquisition opportunities. Additionally, obtaining government approvals for their products is crucial to ensure compliance with regulatory standards.

Recent Developments

• In January 2024, The FDA approved Neuralace Medical’s Axon Therapy, a noninvasive treatment for painful diabetic neuropathy. This therapy uses magnetic peripheral nerve stimulation (mPNS) to alleviate chronic pain caused by nerve damage due to diabetes.

• In October 2023, Boston Scientific secured FDA approval for its WaveWriter Alpha spinal cord stimulation device to treat painful diabetic peripheral neuropathy (PDN), a common complication of diabetes that affects the legs and feet. This expanded indication enables Boston Scientific to enter the growing PDN market, which is expected to reach upto USD5 billion in value by Nevro's forecast, alongside competitors Abbott and Medtronic.

• In January 2023, NeuroMetrix launched DPNCheck 2.0, an enhanced point-of-care device for detecting peripheral neuropathy. Using nerve conduction technology, the device offers rapid, accurate, and quantitative testing, improving early detection and staging of neuropathy, including diabetic peripheral neuropathy. It features user-friendly design improvements like real-time nerve response display, a touchscreen interface, and better temperature compensation.

Global Diabetic Neuropathy Management Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global diabetic neuropathy management market report based on devices, application, end-use, and region:

Devices Outlook (Revenue, USD Million, 2018 - 2030)

• Electrical Stimulation Devices

• Neuro Stimulation Devices

• Nerve Conduction Testing Devices

• Other Devices

Application Outlook (Revenue, USD Million, 2018 - 2030)

• Peripheral Neuropathy

• Autonomic Neuropathy

• Proximal Neuropathy

• Mononeuropathy      

End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Home Healthcare

• Other End-use

Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

o Mexico

• Europe

o UK

o Germany

o France

o Italy

o Spain

o Denmark

o Sweden

o Norway

• Asia Pacific

o Japan

o China

o India

o Australia

o Thailand

o South Korea

• Latin America

o Brazil

o Argentina

• Middle East & Africa

o South Africa

o Saudi Arabia

o UAE

o Kuwait

Order a free sample PDF of the Diabetic Neuropathy Management Market Intelligence Study, published by Grand View Research.

[healthcare-updates-with-sns]

Diabetic Neuropathy Market: Key Trends and Future Opportunities 2024-2032

The Diabetic Neuropathy Market Size was valued at USD 4.36 billion in 2023 and is projected to reach USD 8.38 billion by 2032, growing at a compound annual growth rate (CAGR) of 7.81% over the forecast period 2024-2032. This growth is driven by the increasing prevalence of diabetes, advancements in diagnostic assays and therapeutics, and heightened awareness of chronic complications associated with diabetes. The global diabetic population is steadily rising, emphasizing the need for effective management and treatment solutions.

Get Free Sample Report @ https://www.snsinsider.com/sample-request/3429

Regional Analysis

North America: Dominates the market due to a high prevalence of diabetes, well-established healthcare infrastructure, and significant investment in research and development.

Europe: Exhibits substantial growth attributed to increasing diabetes cases and supportive government initiatives aimed at managing diabetic complications.

Asia-Pacific: Anticipated to experience the fastest growth, driven by a rising diabetic population, improving healthcare facilities, and growing awareness about diabetic neuropathy.

Market Segmentation

By Disorder Type:

Peripheral Neuropathy

Autonomic Neuropathy

Proximal Neuropathy

Focal Neuropathy

By Drug Class:

Antidepressants

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Capsaicin

Opioids

Others

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Key Players:

The Diabetic Neuropathy market players include Abbott, Novartis, Pfizer Inc., Boehringer Ingelheim GmbH, Lupin Pharmaceuticals, Janssen Pharmaceuticals, Inc., Glenmark Pharmaceuticals Ltd., Eli Lilly and Company, Astellas Pharma Inc. & Medtronic PLC & other players.

Key Points

The surge in diabetes cases has heightened the demand for diabetic neuropathy treatments.

Increased awareness of diabetes complications is driving the adoption of neuropathy management procedures.

High costs associated with diabetic neuropathy treatments pose challenges to market growth.

Stringent government regulations may limit the adoption of certain neuropathy procedures.

Technological advancements present lucrative opportunities for market expansion.

Future Scope

Ongoing research and development efforts are focused on innovative treatments such as gene therapy, stem cell therapy, and targeted drug delivery systems, which hold promise for improving or potentially reversing neuropathy symptoms. Emerging therapeutic advancements are enhancing treatment efficacy, while government and non-profit organizations are actively working to raise awareness about early diagnosis and effective management strategies. These initiatives are expected to propel market growth in the coming years.

Conclusion

The diabetic neuropathy market is poised for significant growth, driven by the escalating prevalence of diabetes and continuous advancements in treatment methodologies. Addressing challenges such as high treatment costs and regulatory constraints, while leveraging technological innovations and awareness programs, will be crucial in effectively managing diabetic neuropathy and enhancing patient outcomes.

Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)

Other Related Reports:

Fertility Services Market

Medical Power Supply Market

Post Traumatic Stress Disorder Treatment Market

MRI Guided Neurosurgical Ablation Market

[colinwilson11]

SARM1 Inhibitors Market Will Grow At Highest Pace Owing To Reduced Risk Of Neuronal Death

The SARM1 Inhibitors Market comprises small molecule drugs that can block SARM1 signaling to prevent stress-induced axon degeneration. SARM1 plays a key role in Wallerian degeneration by promoting programmed neuronal injury and death. Inhibition of SARM1 can provide neuroprotection in various neurological disorders like stroke, spinal cord injury, and neurodegenerative diseases. The global demand for neuroprotective drugs is growing due to the rising geriatric population and increasing incidence of neurological conditions.

The SARM1 Inhibitors Market is estimated to be valued at US$ 5 Mn in 2024 and is expected to exhibit a CAGR of 103% over the forecast period 2024-2031.

Key Takeaways

Key players operating in the SARM1 Inhibitors Market are Disarm Therapeutics, Nura Bio, Washington University, and Asha Therapeutics. Disarm Therapeutics is conducting several preclinical studies to evaluate SARM1 inhibitors for treating peripheral neuropathy. The growing prevalence of neurological disorders across the globe is driving the demand for neuroprotective drugs. As per WHO estimates, over 1 billion people suffer from neurological disorders worldwide. Effective neuroprotective therapies can significantly reduce mortality and improve quality of life.

Various technology players are developing novel screening platforms to identify potent and selective SARM1 inhibitors. For instance, Asha Therapeutics is using its proprietary ASSAYready platform to accelerate drug discovery and preclinical development of SARM1 inhibitors. Washington University researchers have also developed a luciferase-based screening assay to identify drug candidates.

Market Trends

One of the key trends in the SARM1 Inhibitors Market is the focus on developing orally bioavailable drugs. Most companies are exploring both intravenous and oral formulations to ensure patient compliance. Oral drugs can enable outpatient treatment and improve accessibility.

Another major trend is the evaluation of SARM1 inhibitors for a wide range of neurotrauma indications. Beyond stroke and spinal cord injuries, companies are investigating the neuroprotective potential in diseases like ALS, multiple sclerosis, and diabetic neuropathy. This can significantly expand the market size over the coming years.

Market Opportunities

The introduction of combination therapies using SARM1 inhibitors is a major opportunity in the market. Combining SARM1 inhibitors with other neuroprotective agents can yield enhanced therapeutic effects. Universities are conducting preclinical studies evaluating synergies with erythropoietin, microtubule stabilizers, and immune modulators. Targeting younger patient populations is another key opportunity. While initial focus is on geriatric neurodegenerative conditions, SARM1 inhibitors may prevent nerve damage after traumatic brain or spinal cord injuries in pediatric patients. This can establish a large patient base.

Impact Of COVID-19 On SARM1 Inhibitors Market Growth

The COVID-19 pandemic has severely impacted the growth of the global SARM1 inhibitors market. During the initial outbreak, the demand for SARM1 inhibitors declined significantly as clinical trials and drug development projects faced disruptions. The travel restrictions and lockdowns imposed worldwide disrupted drug supply chains and halted several clinical trials that were underway to evaluate SARM1 inhibitors for various neurological conditions. This posed major challenges for companies engaged in developing novel SARM1 inhibitor drugs. However, the pandemic also highlighted the need for effective treatment options for neurological disorders, renewing focus on research related to SARM1 inhibition.

As the pandemic situation improved with the roll-out of vaccination programs in 2021-2022, activity in the SARM1 Inhibitors Market regained momentum. Pharmaceutical manufacturers resumed investment in drug development and research projects to advance promising SARM1 inhibitor candidates. Clinical trials that were paused also restarted after implementing necessary safety protocols. The pandemic motivated increased funding towards neuroscience research from both private and public sectors. It is expected that the learnings from the pandemic will help market players better plan future clinical trials and strategize drug supply chain management to make the market more resilient.

Going forward, collaboration between academia and industry is likely to accelerate to efficiently translate basic research discoveries into approved therapies. The long-term outlook for the SARM1 Inhibitors Market remains positive, supported by demographic trends of aging populations and rising prevalence of neurological disorders globally. Commercialization of first-in-class SARM1 inhibitor drugs over the next 3-5 years can propel significant market growth.

Geographical Regions With Highest Value In SARM1 Inhibitors Market

North America currently dominates the SARM1 Inhibitors Market in terms of value, attributed to presence of major drug developers and higher research spending on neurological disease treatments. The United States represents the largest market for SARM1 inhibitors within the region supported by its advanced healthcare infrastructure and patient acceptability for novel drugs.

Europe is the second most lucrative geographical region for SARM1 inhibitors market. Factors such as rising geriatric population, increasing burden of neurodegenerative diseases, and conducive regulatory environment support the market growth within the European countries. Germany, United Kingdom and France constitute some of the key national markets in Europe for SARM1 inhibitors.

Fastest Growing Region For SARM1 Inhibitors Market

The Asia Pacific region is poised to witness the fastest growth in the SARM1 Inhibitors Market over the forecast period from 2024 to 2031. This can be accredited to rapidly developing healthcare industry, rising medical expenditures, and growing focus of international players to tap into the region's large patient pool.

Countries like China, India, South Korea and Japan are expected to drive the high growth owing to their strengthening economic conditions, rising disposable incomes, and increasing government support for neurological disease research. Favorable regulatory guidelines and improving accessibility of innovative drugs indicate immense untapped opportunities for SARM1 inhibitor manufacturers within the Asia Pacific region.

Get more insights on this topic: https://www.pressreleasebulletin.com/sarm1-inhibitors-market-is-estimated-to-witness-high-growth-owing-to-advancements-in-neurodegenerative-treatment-therapeutics/

Author Bio

Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups. (LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)

What Are The Key Data Covered In This SARM1 Inhibitors Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the SARM1 Inhibitors's growth between 2024 and 2031.

:- Accurate calculation of the size of the SARM1 Inhibitors and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- SARM1 Inhibitors Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of SARM1 Inhibitors vendors

FAQ’s

Q.1 What are the main factors influencing the SARM1 Inhibitors?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top SARM1 Inhibitors companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the SARM1 Inhibitors’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

*Note: 1. Source: Coherent Market Insights, Public sources, Desk research 2. We have leveraged AI tools to mine information and compile it

[deshpandeisha]

Understanding Peripheral Neuropathy: Causes, Symptoms, and Types

The global peripheral neuropathy market size was USD 3.61 Billion in 2022 and is expected to register a revenue CAGR of 9.0% during the forecast period. Rise in peripheral neuropathy cases, the increased prevalence of chronic illnesses, and increasing number of pipeline drugs are some of the key factors driving market revenue growth.

The report on Global Peripheral Neuropathy Market added by Emergen Research offers a comprehensive analysis of the recent advancements in the Peripheral Neuropathy industry and trends driving the growth of the market. It is an investigative study covering analysis of market drivers, restraints, challenges, threats, and growth prospects in the global Peripheral Neuropathy market. The global Peripheral Neuropathy market report is a methodical research of the Peripheral Neuropathy market done by extensive primary and secondary research. The fundamental purpose of the Peripheral Neuropathy market report is to offer an accurate and strategic analysis of the Peripheral Neuropathy business sphere.

Get Download Pdf Sample Copy of this Report@ https://www.emergenresearch.com/request-sample/2757

Competitive Terrain:

The global Peripheral Neuropathy industry is highly consolidated owing to the presence of renowned companies operating across several international and local segments of the market. These players dominate the industry in terms of their strong geographical reach and a large number of production facilities. The companies are intensely competitive against one another and excel in their individual technological capabilities, as well as product development, innovation, and product pricing strategies.

The leading market contenders listed in the report are:

Assertio Holdings, Inc, AstraZeneca, Abbott, Cadila Pharmaceuticals, Cipla Inc, DAIICHI SANKYO COMPANY, LIMITED, Dr. Reddy’s Laboratories Ltd, Eli Lilly and Co., Endo International plc, Grünenthal, Hikma Pharmaceuticals PLC, Johnson & Johnson, Inc, Lupin, Novartis AG, Pfizer Inc, Shionogi & Co., Ltd, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, UCB S.A., Viatris Inc

Key market aspects studied in the report:

Market Scope: The report explains the scope of various commercial possibilities in the global Peripheral Neuropathy market over the upcoming years. The estimated revenue build-up over the forecast years has been included in the report. The report analyzes the key market segments and sub-segments and provides deep insights into the market to assist readers with the formulation of lucrative strategies for business expansion.

Competitive Outlook: The leading companies operating in the Peripheral Neuropathy market have been enumerated in this report. This section of the report lays emphasis on the geographical reach and production facilities of these companies. To get ahead of their rivals, the leading players are focusing more on offering products at competitive prices, according to our analysts.

Report Objective: The primary objective of this report is to provide the manufacturers, distributors, suppliers, and buyers engaged in this sector with access to a deeper and improved understanding of the global Peripheral Neuropathy market.

Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now)@ https://www.emergenresearch.com/request-discount/2757

Market Segmentations of the Peripheral Neuropathy Market

This market is segmented based on Types, Applications, and Regions. The growth of each segment provides accurate forecasts related to production and sales by Types and Applications, in terms of volume and value for the period between 2022 and 2030. This analysis can help readers looking to expand their business by targeting emerging and niche markets. Market share data is given on both global and regional levels. Regions covered in the report are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Research analysts assess the market positions of the leading competitors and provide competitive analysis for each company. For this study, this report segments the global Peripheral Neuropathy market on the basis of product, application, and region:

Segments Covered in this report are:

Type Outlook (Revenue, USD Billion; 2019-2032)

Diabetic Peripheral Neuropathy

Chemotherapy-Induced Peripheral Neuropathy

Idiopathic Peripheral Neuropathy

HIV/AIDS Associated Peripheral Neuropathy

Treatment Method Outlook (Revenue, USD Billion; 2019-2032)

Pharmacological Therapies

Pain Relievers

Anti-Seizure Medications

Anti-Depressants

Non-Pharmacological Therapies

Transcutaneous Electrical Nerve Stimulation

Plasma Exchange

Others

Others

Route of Administration Outlook (Revenue, USD Billion; 2019-2032)

Oral

Parenteral

Others

Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/peripheral-neuropathy-market

Major Geographies Analyzed in the Report:

North America (U.S., Canada)

Europe (U.K., Italy, Germany, France, Rest of EU)

Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)

Latin America (Chile, Brazil, Argentina, Rest of Latin America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

ToC of the report:

Chapter 1: Market overview and scope

Chapter 2: Market outlook

Chapter 3: Impact analysis of COVID-19 pandemic

Chapter 4: Competitive Landscape

Chapter 5: Drivers, Constraints, Opportunities, Limitations

Chapter 6: Key manufacturers of the industry

Chapter 7: Regional analysis

Chapter 8: Market segmentation based on type applications

Chapter 9: Current and Future Trends

Request Customization as per your specific requirement@ https://www.emergenresearch.com/request-for-customization/2757

About Us:

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: www.emergenresearch.com

Direct Line: +1 (604) 757-9756

E-mail: sales@emergenresearch.com

Visit for More Insights: https://www.emergenresearch.com/insights

Explore Our Custom Intelligence services | Growth Consulting Services

Trending Titles: Geocell Market | Pancreatic Cancer Treatment Market

Latest Report:  Ceramic Tiles Market | Life Science Analytics Market

[vaiswr]

Peripheral Neuropathy Market Investment Opportunities, Industry Share & Trend Analysis Report to 2032

The slowdown in economic expansion and the rapid shifts in demand will have an even greater impact on industry growth. The COVID-19 pandemic's effects on the entire Peripheral Neuropathy industry are covered in the paper. This study addresses both qualitative and quantitative aspects of the Peripheral Neuropathy market in addition to offering significant statistical data about it. The research study offers a precise prognosis for the keyword market through 2027. The research provides a thorough analysis of both existing and up-and-coming market participants. The report also includes information on the companies' business overviews, product portfolios, and expansion plans.

The global peripheral neuropathy market size was USD 3.61 Billion in 2022 and is expected to register a revenue CAGR of 9.0% during the forecast period. Rise in peripheral neuropathy cases, the increased prevalence of chronic illnesses, and increasing number of pipeline drugs are some of the key factors driving market revenue growth.